tbuckley/cabot-search huggingface dataset:
Neurological Symptoms Among US Diplomats in Cuba
Authors: Christopher C. Muth, Steven L. Lewis
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor <i>PIK3CA</i> Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data
Authors: Dimitrios Zardavas, Luc te Marvelde, Roger L. Milne, Debora Fumagalli, George Fountzilas, Vassiliki Kotoula, Evangelia Razis, George Papaxoinis, Heikki Joensuu, Mary Ellen Moynahan, Bryan T. Hennessy, Ivan Bieche, Lao H. Saal, Olle Stal, Barry Iacopetta, Jeanette Dupont Jensen, Sandra O’Toole, Elena Lopez-Knowles, Mattia Barbaraeschi, Shinzaburo Noguchi, Hatem A. Azim, Enrique Lerma, Thomas Bachelot, Qing Wang, Gizeh Perez-Tenorio, Cornelis J.H. can de Velde, Daniel W. Rea, Vicky Sabine, John M.S. Bartlett, Christos Sotiriou, Stefan Michiels, Sherene Loi
Journal: Journal of Clinical Oncology (2018)

Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall survival (OS) were also assessed, overall and by breast cancer subtypes. Results Data from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787 patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%) received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations occurred in 32% of patients, with significant associations with ER positivity, increasing age, lower grade, and smaller size (all P < .001). Prevalence of PIK3CA mutations was 18%, 22%, and 37% in the ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84; P < .001), with evidence for a stronger effect in the first years of follow-up (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P < .001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); > 10 years: (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA genotype remained significant for improved IDFS ( P = .043), but not for the DDFS and OS end points. Conclusion In this large pooled analysis, PIK3CA mutations were significantly associated with a better IDFS, DDFS, and OS, but had a lesser prognostic effect after adjustment for other prognostic factors.
Oregon’s Death With Dignity Act
Authors: Sarah K. Sperling
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Caldendrin Directly Couples Postsynaptic Calcium Signals to Actin Remodeling in Dendritic Spines
Authors: Marina Mikhaylova, Julia Bär, Bas van Bommel, Philipp Schätzle, PingAn YuanXiang, Rajeev Raman, Johannes Hradsky, Anja Konietzny, Egor Y. Loktionov, Pasham Parameshwar Reddy, Jeffrey Lopez-Rojas, Christina Spilker, Oliver Kobler, Syed Ahsan Raza, Oliver Stork, Casper C. Hoogenraad, Michael R. Kreutz
Journal: Neuron (2018)
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
Authors: Alan Winston, Frank A Post, Edwin DeJesus, Daniel Podzamczer, Giovanni Di Perri, Vicente Estrada, François Raffi, Peter Ruane, Paula Peyrani, Gordon Crofoot, Patrick W G Mallon, Francesco Castelli, Mingjin Yan, Stephanie Cox, Moupali Das, Andrew Cheng, Martin S Rhee
Journal: The Lancet HIV (2018)
Traitement endoscopique des hémorragies digestives secondaires à l'hypertension portale chez les patients cirrhotiques
Authors: J El Atmani, Y Ismail, S Oubaha, Z Samlani, K Krati
Journal: Endoscopy (2018)

L'hémorragie digestive secondaire à l'hypertension portale (HTP) constitue une urgence vitale fréquente et la principale cause de décès chez les patients cirrhotiques. La prise en charge (PEC) de cette hémorragie est multidisciplinaire reposant dans la majorité des cas sur la réanimation médicale et l'hémostase endoscopique.
Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Apostolos Tsimploulis, Phillip H. Lam, Cherinne Arundel, Steven N. Singh, Charity J. Morgan, Charles Faselis, Prakash Deedwania, Javed Butler, Wilbert S. Aronow, Clyde W. Yancy, Gregg C. Fonarow, Ali Ahmed
Journal: JAMA Cardiology (2018)

Lower systolic blood pressure (SBP) levels are associated with poor outcomes in patients with heart failure. Less is known about this association in heart failure with preserved ejection fraction (HFpEF).
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
Authors: Stuart E. Siegel, Wendy Stock, Rebecca H. Johnson, Anjali Advani, Lori Muffly, Dan Douer, Damon Reed, Mark Lewis, David R. Freyer, Bijal Shah, Selina Luger, Brandon Hayes-Lattin, Jerry J. Jaboin, Peter F. Coccia, Daniel J. DeAngelo, Nita Seibel, Archie Bleyer
Journal: JAMA Oncology (2018)

The incidence of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adolescent and young adult (AYA) patients (age range, 15-39 years) in the United States is increasing at a greater rate than in younger or older persons. Their optimal treatment has been increasingly debated as pediatric regimens have become more widely used in the age group. This review compares the basic features of pediatric and adult chemotherapy regimens for ALL and LBL, recognizes and describes the challenges of the pediatric regimen, and suggests strategies to facilitate its adoption for AYAs with ALL and LBL.All but 2 of 25 published comparisons of outcomes with pediatric and adult regimens for ALL and LBL in AYAs and 1 meta-analysis favor the pediatric regimen. After more than a half-century of clinical trials of the pediatric regimens, including at least 160 phase 3 trials in the United States, the pediatric regimens have become far more complex than most adult regimens. Asparaginase, a critical component of the pediatric regimens, is more difficult to administer to AYAs (and older patients) but nonetheless has a favorable benefit to toxicity ratio for AYAs. A dramatic reduction in outcome of ALL and LBL during the AYA years (the "survival cliff") is coincident with similar reductions in proportions of AYAs referred to academic centers and enrolled on clinical trials (the "accrual cliff" and "referral cliff").The accumulating data increasingly support treating AYAs with ALL and LBL with a pediatric-inspired regimen or an approved institutional or national clinical trial tailored for this patient group. A need to develop clinical trials specifically for AYAs and to encourage their participation is paramount, with a goal to improve both the quantity and quality of survival.
Risk of Dementia in Adults With Congenital Heart Disease
Authors: Carina N. Bagge, Victor W. Henderson, Henning B. Laursen, Kasper Adelborg, Morten Olsen, Nicolas L. Madsen
Journal: Circulation (2018)

Background: More children with congenital heart disease (CHD) are surviving to adulthood, and CHD is associated with risk factors for dementia. We compared the risk of dementia in CHD adults to that of the general population. Methods: In this cohort study, we used medical registries and a medical record review covering all Danish hospitals to identify adults with CHD diagnosed between 1963 and 2012. These individuals with CHD were followed from January 1, 1981, 30 years of age, or date of first CHD registration (index date for matched members of the general population cohort) until hospital diagnosis of dementia, death, emigration, or end of study (December 31, 2012). For each individual with CHD, we identified 10 members of the general population utilizing the Danish Civil Registration System matched on sex and birth year. We computed cumulative incidences and hazard ratios (HRs) of dementia, adjusting for sex and birth year. Results: The cumulative incidence of dementia was 4% by 80 years of age in 10 632 adults with CHD (46% male). The overall HR comparing adults with CHD with the general population cohort was 1.6 (95% confidence interval [CI], 1.3−2.0). The HR among individuals with CHD without extracardiac defects was 1.4 (95% CI, 1.1−1.8). Adults with mild-to-moderate CHD had an HR of 1.5 (95% CI, 1.1−2.0), whereas the HR was 2.0 (95% CI, 1.2−3.3) for severe CHD, including univentricular hearts. The HR for early onset dementia (&lt;65 years of age) was 2.6 (95% CI, 1.8−3.8), whereas the late-onset HR was 1.3 (95% CI, 1.0−1.8). Conclusions: CHD was associated with an increased risk of dementia compared with the general population, in particular for early onset dementia. Further understanding of dementia risk in the population with CHD is a potential target for future investigation.
New Statistical Editor—January 2018
Authors: Melina R. Kibbe
Journal: JAMA Surgery (2018)

JAMA Surgery thanks Alfred W. Rademaker, PhD, for his service as Statistical Editor from 2015 through 2017. Dr Rademaker will be greatly missed. His contributions to the science have undoubtedly contributed to the success of JAMA Surgery. Good luck with your future endeavors, Fred!
Impact de la surveillance active sur les indicateurs de qualité de la coloscopie
Authors: R Saade, M Chemali, M Achkar, S Khalife, B Hotayt, J Amara, P Rassam, C Yaghi
Journal: Endoscopy (2018)

La coloscopie s'est avérée être dans la dernière décennie le moyen de dépistage le plus efficace du cancer colorectal (CCR). Elle garde cependant plusieurs limitations, et l'application de certains critères de qualité permet d'améliorer sa performance. Un temps de retrait (TR) de 6 minutes au minimum est recommandé et le taux de détection des adénomes (TDA) augmente avec le TR. Le TDA procure un indice fiable d'une inspection méticuleuse de la muqueuse, et est inversement associé au développement de cancers d'intervalle. But du travail: évaluer l'impact d'une surveillance du TR connue de l'endoscopiste sur la qualité de la coloscopie, mesurée par le TDA.
Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer.
Authors: Brandon Matthew Meyers, Humaid Obaid Al-Shamsi, Alvaro Tell Figueredo
Journal: Journal of Clinical Oncology (2013)

3548 Background: Colon cancer is potentially curable by surgery in the early stages of the disease. Adjuvant chemotherapy improves disease-free and overall survival in patients with stage III disease, but the magnitude of benefit in stage II colon cancer is less clear. A previous Cochrane systematic review and meta-analysis (SR/MA) found improved disease-free, but not overall survival (Figueredo et al., 2008). An updated SR/MA was performed to determine the effects of adjuvant chemotherapy on disease-free and overall survival in patients with stage II colon cancer. Methods: Relevant databases (MEDLINE, EMBASE, and Cochrane) were independently searched by all authors, using the same search strategy employed in the original study (1/1988 to 9/2012). Randomized trials containing data on stage II colon cancer patients undergoing adjuvant 5-fluorouracil (5FU) chemotherapy versus observation were included. Pooled results were expressed as hazard ratios (HR) whenever possible, or risk ratios (RR), with 95% confidence intervals (95%CI) using a random effects model. Results: Seven studies were identified, and included in the final SR/MA. Six of the 7 studies were included in the disease-free survival analysis (n=4587). Adjuvant 5FU was associated with better disease-free survival (RR 0.84 (95%CI 0.75-0.94)). All 7 studies (n=5353) were included in the overall survival analysis showing an improvement with adjuvant 5FU (HR 0.87 (95%CI 0.78-0.97)). There was no evidence of heterogeneity across the studies (I 2 = 0% for all analyses). Conclusions: In stage II colon cancer, adjuvant 5FU chemotherapy statistically improves both disease-free and overall survival. Our SR/MA demonstrates, for the first time, an overall survival advantage with adjuvant chemotherapy in stage II colon cancer.
P072 Irf1 is critical for the inflammatory gene expression in fibroblast-like synoviocytes
Authors: M Bonelli, S Hayer, K Dalwigk, B Niederreiter, T Pap, J Smolen, H Kiener, T Karonitsch
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Introduction</h3> Fibroblast-like synoviocytes (FLS) are increasingly recognised as major pathogenic cells in synovial inflammation of patients with Rheumatoid Arthritis (RA). In response to pro-inflammatory stimuli, such as TNF, FLS produce vast amounts of cytokines and chemokines that help to recruit and activate immune cells and drive the local inflammatory process. The pathways and transcription factors that determine the inflammatory response in FLS are, however, largely unexplored. <h3>Objectives</h3> To investigated the potential contribution of the transcription-factor IRF1 to the inflammatory gene expression in FLS. <h3>Methods</h3> Expression of IRF1 in synovial tissue samples (12 RA and 8 osteoarthritis (OA) patients) was assessed by immunohistochemistry (IHC). Moreover, FLS were isolated according to established protocols and cultured using 2-D or 3-D culture techniques. IRF1expression in response to TNF was determined by western blots, qPCR, immunofluorescence microscopy or IHC. FLS were also stimulated with TNF in the presence or absence of IRF1 siRNA pools. Expression of pro-inflammatory cytokines and chemokines was measured by qPCR. <h3>Results</h3> IRF1 expression was significantly increased in rheumatoid synovial tissues as compared to patients with OA on protein level. RA-FLS stimulation with TNF <i>ex vivo</i> caused rapid upregulation of IRF1 and proved the involvement of TNF in the regulation of IRF1. Immunofluorescence analysis further revealed that IRF1 was mainly localised in the nucleus of TNF-stimulated FLS. Moreover, also chronic TNF exposure of FLS grown in a 3-D synovial tissue culture system promoted the expression of IRF1. siRNA-mediated knockdown of IRF1 in FLS significantly reduced the TNF-induced expression of pro-inflammatory cytokines and chemokines, such as IL6, CCL7, CXCL11 and TNFSF13B, which confirmed the role of IRF1 as a critical regulator of proinflammatory genes in RA FLS. <h3>Conclusions</h3> Our data reveal that IRF1 is crucial for the inflammatory response of FLS and support the idea that IRF1 might be an exciting therapeutic target in patients with RA. <h3>Disclosure of interest</h3> None declared
Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17
Authors: Ainara Mira-Iglesias, F Xavier López-Labrador, Beatriz Guglieri-López, Miguel Tortajada-Girbés, Víctor Baselga-Moreno, Laura Cano, Juan Mollar-Maseres, Mario Carballido-Fernández, Germán Schwarz-Chavarri, Javier Díez-Domingo, Joan Puig-Barberà
Journal: Eurosurveillance (2018)

Introduction Seasonal influenza vaccination is widely recommended for people with risk factors, especially for people who are elderly. However, influenza vaccine effectiveness (IVE) varies year after year because of the variable antigenic composition of the circulating viruses and the vaccine composition. Methods: We summarise the results of IVE and the impact of previous vaccination among subjects 60 years of age and over in a multicentre prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI) in Spain. We applied the test-negative design taking laboratory-confirmed influenza as outcome and vaccination status as exposure. Information about potential confounders was obtained from clinical registries or directly from patients. Results: Adjusted IVE was 19% (95% confidence interval (CI): −15 to 43). For patients vaccinated in the current season but not in the two previous seasons, effectiveness was 49% (95% CI: −20 to 78) and for patients vaccinated in the current and any of two previous seasons, effectiveness was 29% (95% CI: −3 to 52). For those patients not vaccinated in the current season but vaccinated in any of the two previous seasons, effectiveness was 53% (95% CI: 8 to 76). Conclusions: Our data show a low vaccine effectiveness for the 2016/17 influenza season.
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer
Authors: Marni B. Siegel, Xiaping He, Katherine A. Hoadley, Alan Hoyle, Julia B. Pearce, Amy L. Garrett, Sunil Kumar, Vincent J. Moylan, Claudia M. Brady, Amanda E.D. Van Swearingen, David Marron, Gaorav P. Gupta, Leigh B. Thorne, Niamh Kieran, Chad Livasy, Elaine R. Mardis, Joel S. Parker, Mengjie Chen, Carey K. Anders, Lisa A. Carey, Charles M. Perou
Journal: Journal of Clinical Investigation (2018)

Breast cancer metastasis remains a clinical challenge, even within a single patient across multiple sites of the disease. Genome-wide comparisons of both the DNA and gene expression of primary tumors and metastases in multiple patients could help elucidate the underlying mechanisms that cause breast cancer metastasis. To address this issue, we performed DNA exome and RNA sequencing of matched primary tumors and multiple metastases from 16 patients, totaling 83 distinct specimens. We identified tumor-specific drivers by integrating known protein-protein network information with RNA expression and somatic DNA alterations and found that genetic drivers were predominantly established in the primary tumor and maintained through metastatic spreading. In addition, our analyses revealed that most genetic drivers were DNA copy number changes, the TP53 mutation was a recurrent founding mutation regardless of subtype, and that multiclonal seeding of metastases was frequent and occurred in multiple subtypes. Genetic drivers unique to metastasis were identified as somatic mutations in the estrogen and androgen receptor genes. These results highlight the complexity of metastatic spreading, be it monoclonal or multiclonal, and suggest that most metastatic drivers are established in the primary tumor, despite the substantial heterogeneity seen in the metastases.
Endoscopic removal of two magnets impacted in the lower esophagus and gastric fundus
Authors: Liansong Ye, Zhengbing Yang, Jiang Du, Qishan Zeng, Xianglei Yuan, Yuhang Zhang, Bing Hu
Journal: Endoscopy (2018)

A 13-year-old healthy child was referred with a 12-day history of epigastric pain following the inadvertent ingestion of two round magnets. Radiographic inspection on the first day demonstrated two separate foreign bodies in the lower esophagus and gastric fundus ([Fig. 1]), which did not pass spontaneously after 3 days of follow-up. Upper gastrointestinal endoscopy on the fourth day revealed the formation of an esophagogastric fistula ([Fig. 2]), but conventional endoscopic methods failed to remove the impacted magnets after repeated attempts. The patient and his parents refused a surgical operation, therefore another endoscopic intervention was performed.
APRIL, BAFF, and TGF-β Concentrations in Colostrum Correlate with Allergic Disease Outcome
Authors: Puja Sood, John J. Varrone, Anna K. Kukkonen, Mikael Kuitunen, Erkki Savilahti, Antti E. Seppo, Kirsi M. Jarvinen-Seppo
Journal: Journal of Allergy and Clinical Immunology (2018)
European families reveal MHC class I and II associations with autoimmune-mediated congenital heart block
Authors: Nikolaos C Kyriakidis, Ingrid Kockum, Heikki Julkunen, Ariela Hoxha, Stina Salomonsson, Lauro Meneghel, Cathrine Ebbing, Alexander Dilthey, Marianne Eronen, Sara De Carolis, Torvid Kiserud, Amelia Ruffatti, Juha Kere, Sabrina Meisgen, Marie Wahren-Herlenius
Journal: Annals of the Rheumatic Diseases (2018)

Congenital heart block (CHB) may develop in the fetus of Ro/SSA autoantibody-positive women. A population-based recurrence rate of only 12% however suggests that factors other than maternal autoantibodies influence the risk of developing CHB.1 In the present study, we aimed to identify genetic contribution to the disease by analysing HLA associations in European families with a Ro/SSA antibody-positive mother and at least one child affected by CHB.

HLA allele genotypes were imputed for 173 families comprising 635 individuals (291 parents, 173 cases and 167 unaffected siblings) from Sweden, Norway, Finland and Italy (online supplementary table 1) based on 5636 tag SNPs. Parental HLA allele transmission frequencies to patients with CHB were assessed and OR and significance of the association with CHB calculated. We considered nominal P values <0.05 suggestive of significance, and P values below the threshold of Bonferroni correction for multiple testing, or if the association had been previously reported at P<0.05, significant. Detailed information on patients and methods are available online (online supplementary methods).

### Supplementary file 1

[annrheumdis-2018-212953-SP1.docx] 

### Supplementary file 2

[annrheumdis-2018-212953-SP2.docx] 

In the MHC class I gene locus, we replicated the previously identified2 protective association of HLA-Cw*06 (OR 0.22 (0.07–0.67), P=0.003) …